İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2022 · article

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

ISSN2473-9529
YÖKSİS OpenAlex Açık erişim · gold
Yıl2022
Atıf20OpenAlex
Atıf17Semantic Scholar · 2 etkili
Yüzdelik%87,6
FWCI2,141,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıBlood Advances
  • Katalog eşleşmesi (ISSN)Blood Advances
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, or who were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported from patients who received ≥1 dose of study treatment and completed ≥1 PRO assessment. The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every 12 weeks thereafter. Prespecified end points included least squares mean (LSM) changes from baseline to week 24 and time to true deterioration (TTD; ≥10-point decline from baseline). Comparisons were evaluated using 2-sided P values uncontrolled for multiplicity. High compliance at baseline (>90%) and through week 24 (>80%) was demonstrated across treatment groups (PRO analysis set: pembrolizumab, n = 146; BV, n = 150). The EORTC QLQ-C30 global health status (GHS)/quality of life (QoL) score improved from baseline to week 24 on pembrolizumab and worsened on BV and demonstrated significant LSM differences at 24 weeks (GHS/QoL: 8.60 [95% confidence interval, 3.89-13.31]; P = .0004). Significant improvements were observed in each QLQ-C30 domain except emotional and cognitive functioning. Compared with BV, pembrolizumab prolonged TTD for GHS/QoL (hazard ratio, 0.40 [95% CI, 0.22-0.74]; P = .003) and each QLQ-C30 domain except cognitive functioning. In conclusion, pembrolizumab demonstrated overall improvements in PROs of HRQoL measures over BV in the KEYNOTE-204 study. These data and previously reported efficacy results support pembrolizumab as the preferred treatment option for patients with R/R cHL who are ineligible for or experience relapse after ASCT.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

20atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 1 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2023 Sequencing novel agents in the treatment of classical hodgkin lymphoma.Atıf 0 · OpenAlex

Yazarlar

18
  1. Pier Luigi Zinzani 1
  2. Radhakrishnan Ramchandren 2
  3. Armando Santoro 3
  4. Ewa Paszkiewicz-Kozik 4
  5. Robin Gasiorowski 5
  6. Nathalie A Johnson Nathalie A Johnson 6
  7. Jose S R de Oliveira 7
  8. Valeria Buccheri 8
  9. Guilherme Fleury Perini 9
  10. Michael Dickinson 10
  11. Andrew McDonald 11
  12. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 12
  13. Naohiro Sekiguchi 13
  14. Ying Zhu 14
  15. Monika Raut 15
  16. Todd L Saretsky 16
  17. Akash Nahar 17
  18. John Kuruvilla 18